These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Applicability of phase I trial results in the design of phase II and III biological response modifier trials. Pinsky CM Cancer Treat Rep; 1985 Oct; 69(10):1171-3. PubMed ID: 4042095 [No Abstract] [Full Text] [Related]
25. Biological response modifiers for the therapy of cancer. Herberman RB Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067 [TBL] [Abstract][Full Text] [Related]
26. Ethical issues in cooperative cancer therapy trials from a statistical viewpoint. II. Specific issues. Shuster JJ; Krischer JP; Boyett JM Am J Pediatr Hematol Oncol; 1985; 7(1):64-70. PubMed ID: 4037245 [TBL] [Abstract][Full Text] [Related]
27. Practical side of multistage clinical trials for screening new agents. Herson J Cancer Treat Rep; 1983 Jan; 67(1):71-5. PubMed ID: 6616494 [TBL] [Abstract][Full Text] [Related]
30. Improving the efficacy of cancer immunotherapy. Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214 [TBL] [Abstract][Full Text] [Related]
31. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
32. Immunological monitoring and clinical trials of biological response modifiers. Baseler MW; Kopp WC; Urba WJ Cancer Chemother Biol Response Modif; 1993; 14():249-83. PubMed ID: 7508729 [No Abstract] [Full Text] [Related]
33. Interpreting cancer vaccine clinical trials. Dranoff G J Gene Med; 1999; 1(2):80-3. PubMed ID: 10738571 [TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy of cancer today and first trials of "modifiers of host-tumor relations"]. Mathé G Rev Prat; 1981 Oct; 31(43):3057-60 passim. PubMed ID: 6170108 [No Abstract] [Full Text] [Related]
35. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Brostjan C; Bayer A; Zommer A; Gornikiewicz A; Roka S; Benkö T; Yaghubian R; Jakesz R; Steger G; Gnant M; Friedl J; Stift A Cancer; 2003 Nov; 98(10):2291-301. PubMed ID: 14601101 [TBL] [Abstract][Full Text] [Related]
36. Current issues in dendritic cell cancer immunotherapy. López JA; Hart DN Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for cancer: focusing on developing treatments rather than drugs. Sznol M Curr Opin Investig Drugs; 2001 Jul; 2(7):957-8. PubMed ID: 11757798 [No Abstract] [Full Text] [Related]
38. Therapeutic vaccine trails in Thailand. Churdboonchart V J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562 [TBL] [Abstract][Full Text] [Related]
39. [Immunotherapy of solid tumors. Current status and prospects]. Valente MG; Tagliaferri F; Stipa F; Arklins K; Cesareo S; Sirovich I Recenti Prog Med; 1996; 87(7-8):358-61. PubMed ID: 8975338 [TBL] [Abstract][Full Text] [Related]